Moxifloxacin (0.5% w/v) is a sterile, topical ophthalmic solution containing a fourth-generation fluoroquinolone antibiotic. It is a broad-spectrum bactericidal agent specifically formulated for the treatment of bacterial infections of the eye. In the Indian context, it is a first-line treatment for bacterial conjunctivitis and is widely used pre- and post-operatively in ophthalmic surgeries to prevent infection.
Adult: Bacterial Conjunctivitis: Instill 1 drop into the affected eye(s) 3 times daily for 5-7 days. Bacterial Keratitis: 1 drop every 15-30 minutes initially while awake, then reduced frequency as per physician's advice. Post-op Prophylaxis: 1 drop 4 times daily starting 1 day before surgery, day of surgery, and for a few days after.
Note: 1. Wash hands. 2. Tilt head back. 3. Gently pull lower eyelid to form a pouch. 4. Instill prescribed drops without touching the dropper tip to eye or any surface. 5. Close eyes gently for 1-2 minutes, applying gentle pressure to the nasolacrimal duct (inner corner of eye) to minimize systemic absorption. 6. Wait at least 5-10 minutes before instilling any other eye medication.
Moxifloxacin is a bactericidal antibiotic that inhibits two essential bacterial type II topoisomerase enzymes: DNA gyrase (primarily in Gram-negative bacteria) and topoisomerase IV (primarily in Gram-positive bacteria). Inhibition of these enzymes interferes with DNA replication, transcription, repair, and recombination, leading to rapid bacterial cell death.
Pregnancy: Pregnancy Category C (US FDA). Animal studies show fetal toxicity. No adequate, well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. In India, use is generally avoided unless strongly indicated.
Driving: May cause transient blurred vision immediately after instillation. Patients should not drive or operate machinery until vision clears.
| Other topical ophthalmic solutions (e.g., corticosteroids, NSAIDs, other antibiotics) | Physical/chemical incompatibility if mixed. May alter corneal penetration. | Moderate |
| Oral Anticoagulants (e.g., Warfarin) | Theoretical interaction due to systemic absorption; may potentiate effect. Monitor INR. | Low |
| Corticosteroids (topical ocular) | May mask or enhance infection. Use combination with caution. | Moderate |
| Metal cations (Oral: Iron, Zinc, Calcium, Magnesium, Aluminum) | Can chelate with systemically absorbed moxifloxacin, reducing absorption. Separate administration by 2-4 hours if systemic therapy is concurrent. | Moderate |